MCL Drug Tracker

12 therapies for mantle cell lymphoma. Approval status, mechanisms, key trials, and linked researchers.

BTKi

Ibrutinib

Imbruvica · BTK (Bruton's tyrosine kinase)

FDA: ApprovedEMA: Approved

Relapsed/refractory MCL; frontline in combination (SHINE)

Acalabrutinib

Calquence · BTK

FDA: ApprovedEMA: Approved

Relapsed/refractory MCL after at least one prior therapy

Zanubrutinib

Brukinsa · BTK

FDA: ApprovedEMA: Approved

Relapsed/refractory MCL

BTKi (non-covalent)

Pirtobrutinib

Jaypirca · BTK

FDA: Approved

Relapsed/refractory MCL after at least two prior therapies including a covalent BTK inhibitor

BCL2i

Venetoclax

Venclexta · BCL-2

FDA: Off-label in MCL

Used in combination regimens for R/R MCL (not FDA-approved specifically for MCL)

CAR-T

Brexucabtagene autoleucel

Tecartus · CD19

FDA: ApprovedEMA: Approved

Relapsed/refractory MCL after BTK inhibitor therapy

Lisocabtagene maraleucel

Breyanzi · CD19

FDA: Under investigation for MCL

Under investigation for MCL

Bispecific antibody

Glofitamab

Columvi · CD20 / CD3

FDA: Under investigation for MCL

Under investigation for MCL

Anti-CD20 antibody

Rituximab

Rituxan / MabThera · CD20

FDA: Approved

Backbone of frontline and maintenance therapy in MCL

Anti-CD20 antibody (type II)

Obinutuzumab

Gazyva · CD20

FDA: Off-label in MCL

Used in combination regimens for MCL, particularly with venetoclax and BTKi

Immunomodulator

Lenalidomide

Revlimid · Cereblon (CRBN)

FDA: Approved

Relapsed/refractory MCL; frontline chemo-free with rituximab

Proteasome inhibitor

Bortezomib

Velcade · 26S proteasome

FDA: Approved

Relapsed/refractory MCL